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Abstract
Pulmonary arterial hypertension (PAH) is a chronic pulmonary vascular disease characterized by 
increased pulmonary arterial pressure and pulmonary arterioles remodeling. Some studies have dis-
covered the relationship between sympathetic nerves (SNs) and pathogenesis of PAH. This review is 
aimed to illustrate the location and components of SNs in the pulmonary artery, along with different 
methods and effects of pulmonary artery denervation (PADN). Studies have shown that the SNs distrib-
uted mainly around the main pulmonary artery and pulmonary artery bifurcation. And the SNs could 
be destroyed by three ways: the chemical way, the surgical way and the catheter-based way. PADN can 
significantly decrease pulmonary arterial pressure rapidly, improve hemodynamic varieties, and then 
palliate PAH. PADN has been recognized as a prospective and effective therapy for PAH patients, espe-
cially for those with medication-refractory PAH. However, further enlarged clinical studies are needed 
to confirm accurate distribution of SNs in the pulmonary artery and the efficacy of PADN. (Cardiol J  )
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Introduction
Pulmonary arterial hypertension (PAH), charac-
terized by mean pulmonary artery pressure (mPAP) 
≥ 25 mmHg at rest, pulmonary artery wedge pres-
sure (PAWP) ≤ 15 mmHg and pulmonary vascular 
resistance (PVR) > 3 Wood units [1], is a disease 
induced by a wide range of causes, which makes it 
difficult to formulate an appropriate therapeutic plan 
and receive great responses for PAH patients [2]. 
Up till the present, most patients can only rely 
on combined targeted medicine, however, not all 
patients can be relieved [2, 3]. Besides, the 1-year, 
3-year and 5-year survival rate of medium to high- 
-risk patients treated by target therapy are 90%, 61%, 
43% [4], and side effects of targeted medicine are not 
tolerable in a considerable number of patients. Thus, 
these patients are eager to acquire better therapies. 
Recently, pulmonary artery denervation (PADN), 
as a novel therapy, has gradually proved beneficial 
to improve hemodynamic measurements in animal 
models and in PAH patients through regulating the 
autonomic nervous system [5]. Previous studies 
have proved that PADN can significantly decrease 
pulmonary arterial pressure rapidly, and then pal-
liate the development of PAH through destroying 
the sympathetic nerves (SNs) of the pulmonary 
artery (PA) [6].
Figure 1. Distribution of sympathetic nerves (SNs) of 
pulmonary artery (PA) in different races. In dogs, most 
nerves (yellow spots) are distributed in posterior wall of 
main pulmonary artery (MPA) and left pulmonary artery 
(LPA), while in swine (gray spots), the SNs are distrib-
uted mostly in posterior and right of MPA. Besides, in 
PA of rats, the components of SNs around PA include 
many TH-positive nerve fibers (red spots), NPY-positive 
nerve fibers (purple spots) and a few CGRP-positive 
nerve fibers (green spots). TH — tyrosine hydroxylase; 
NPY — neuropeptide-Y; CGRP — calcitonin-gene–re-
lated peptide; RPA — right pulmonary artery.
2 www.cardiologyjournal.org
Cardiology Journal 20XX, Vol. XX, No. X
Sympathetic nerves along  
the pulmonary artery
The autonomic nervous system consists of 
sympathetic and parasympathetic parts, which are 
regulated by various neural and endocrine factors [7]. 
The sympathetic nervous system (SNS) arises 
from the spinal cord (T1-L2), and postganglionic 
neurons administrate the pulmonary vascular sys-
tems [7, 8]. Studies have proved that the compo-
nents of SNs around PA include many tyrosine 
hydroxylase (TH)-positive, neuropeptide-Y (NPY)-
-positive and a few calcitonin-gene–related peptide 
(CGRP)-positive nerve fibers in rat models and 
in humans [9]. Thus, when SNS is activated, the 
SNs can locally release neurohormones to enhance 
the vascular tone so that the PA pressure will be 
quickly elevated. Furthermore, chronic inflamma-
tion is known as a critical factor contributing to 
the progress of PAH [10], and de Juan et al. [11] 
has investigated that sympathetic nerves of ar-
teries play an important role in inflammation. 
Therefore, the over-activation of SNS [12] may 
accelerate the development of PAH via regulating 
the inflammation. 
Rothman et al. [13] deemed that SNs around 
the main pulmonary artery (MPA) and PA bifurca-
tion were relatively larger than those around the 
left pulmonary artery (LPA) or right pulmonary 
artery (RPA). Although there is not enough evi-
dence about the distribution of SNs around PA in 
humans, most animal studies also represented 
that SNs distributed mostly around MPA and PA 
bifurcation [9, 14–16], while diverse races may 
have a little difference in the distribution site 
of SNs. Currently, many animals can be used as 
PAH models, and mainly include two animals. Big 
animals, including swine [16, 17], dogs [14, 15], 
sheep [18], rabbits [19] and so on, which are easier 
to operate on because of their larger vessels, bet-
ter tolerance to surgical injury, higher degree of 
the similarity to humans, but the cost in time and 
money is also much higher. Small animals, such as 
mice and rats [9, 20], are more suitable for surgi-
cal models, because they can recover quickly and 
a have stronger anti-infection ability, but skilled 
operators are needed. 
Heretofore, some studies have shown the 
distribution of SNs around the PA in swine, dog 
and rat models (Fig. 1). Rothman et al. [16] showed 
that most nerves are located approximately 1 to 
3 mm from the luminal aspect in the MPA of swine. 
Besides, the diameter of SNs is greater than those 
in the distal PA. In the LPA and RPA, almost all 
nerves are located less than 1 mm away from intra-
artery surface. There are two distal boundaries, 
including the ostium of left posterior artery and 
right posterior descending artery. The nerve bun-
dles are located in the posterior and right of MPA 
and posterior and lateral of the RPA [16]. But in 
dogs, Zhou et al. [15] reported that PA sympathetic 
nerve bundles are located in the left of MPA, and 
most branches were distributed in the posterior 
wall of MPA and LPA, which is different from the 
distribution of SNs in swine. Furthermore, Huang 
et al. [9] investigated that the distribution of nerves 
was mainly in the adipose and connective tissues in 
rats, especially located in posterior and right ante-
rior of MPA and PA bifurcation, which was the same 
with the distribution of SNs in swine. Compared 
with normal rats, the area of SNs distribution was 
significantly larger in the PAH rats, and the SNs 
of PAH rats mainly located in posterior and right 
anterior of MPA and PA bifurcation.
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Pulmonary artery denervation
Pulmonary artery denervation is aimed at 
destroying the anatomic structures and functions 
of SNs along the PA by three methods, including 
chemical denervation, surgical denervation and 
catheter-based denervation. Since 1980, Juratsch 
et al. [21] found that elevation of mPAP increased 
by balloon distension of MPA can be abolished by 
destroying SNs distributed around PA bifurcation 
via surgical or chemical measures [21]. From then 
on, more and continuing studies are conducted to 
search for the best way to perform PADN (Central 
illustration).
Chemical denervation
Chemical denervation is performed via using 
the SNs blocking drugs to damage nerves around 
PA by intravenous infusion [21] or intraperito-
neal injection [22]. To date, there have only been 
a few animal studies referring to chemical PADN, 
most of the studies used 6-hydroxydopamine 
(6-OHDA), a mediator of adrenergic nerves, to 
destroy the activity of SNs [22]. Juratsch et al. [21] 
has performed chemical denervation with 8 dogs, 
and then compared the increments of mPAP post 
balloon inflation in MPA. After destroying the 
pulmonary adrenergic nerves, the responses to bal-
loon inflation in MPA was relieved, and increased 
the value of pulmonary arterial pressure (PAP) 
and PVR all declined markedly when compared 
with before denervation in these dogs [21]. There 
is no doubt that this way is the most convenient, 
while the side effects cannot be ignored. Jiang et 
al. [22] has shown that chemical sympathectomy 
with administration of 6-OHDA caused dysregu-
lation of the cardiac autonomic nervous system 
and myocardial injury. Moreover, administration 
of 6-OHDA can produce selective degeneration 
of adrenergic nerve terminals and blockades or 
destroying adrenergic receptor sites [23] which 
consisted of the pathogenesis of diabetes mellitus. 
Thus, it is necessary to find a new drug, which is 
only plays a role in SNs around PA, or find a new 
way to make the drug to only influence PA nerves. 
Recently, there have been many studies trying to 
perform denervation with magnetic nanoparticles 
(MNP) [24]. Yu et al. [25] has done autonomic den-
ervation in four major atrial ganglionated plexi (GP) 
suppressed atrial fibrillation with MNP. They also 
successfully ablated GP by external electromagnet 
pulled Ca-MNP to the targeted GP after an injected 
Ca-MNP in the coronary artery [26]. Thus, further 
studies may conduct an active targeting magnetic 
nanoparticle with 6-OHDA, then using magnetic 
material in vitro guiding MNP with 6-OHDA in 
MPA and PA bifurcation. Since aminopeptidase P 
(APP) has been confirmed specifically distributed 
in PA endothelium [27], an active targeting drug 
delivery system can be considered, such as APP 
antibody-decorated nanoparticles with 6-OHDA 
loading.
Central illustration. Schematic diagram summarizing principles and methods of pulmonary artery denervation 
(PADN). The area of sympathetic nerves (SNs) distribution was significantly larger in the pulmonary arterial hyperten-
sion (PAH) animals and patients. PADN can destroy those SNs and then palliate PAH; PA — pulmonary artery.
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Surgical denervation
With further research being conducted, the 
distribution of SNs has been clearly depicted that 
many nerves located in the adipose and connective 
tissues of PA adventitia [28]. The performance 
of surgical denervation is mainly via removing 
adipose and connective tissues of PA adventitia. 
Juratsch et al. [21] performed surgical denerva-
tion in dogs with elevated PAP when the balloon 
was inflated in the MPA. After denervation, both 
systolic and diastolic pulmonary artery pressure of 
these dogs did not significantly change when the 
balloon inflated. Transthoracic pulmonary artery 
denervation (TPADN) is more accurate and direct, 
after thoracotomy in the left third intercostal space, 
the adipose and connective tissues around the 
trunk and branches of MPA were exfoliated using 
microsurgical techniques. The main PA trunk and 
bifurcation and the proximal regions of the LPA 
and RPA were the key stripping areas for TPADN. 
Compared with the sham group, the mPAP of the 
test group decreased significantly after denerva-
tion. Furthermore, they demonstrated that the 
muscularization rate declined after denervation [9]. 
Although TPADN was a more effective way to 
reduce mPAP in monocrotaline PAH rat models, 
still the largest limitation cannot be ignored that 
the surgery itself is an invasive way with high risks, 
especially for those who cannot afford anesthesia, 
which makes it very difficult to apply for PAH pa-
tients, so a less invasive PADN method is needed.
Catheter-based denervation
Catheter-based denervation is already applied 
to PAH patients for its micro-traumatic, low-risk 
and quick effect. Many animal studies and clinical 
studies have proved the curative effect of ablation 
[29]. After inserting a sheath through femoral vein 
and advancing to MPA and PA bifurcation after PA 
angiography, then the PADN catheter was advanced 
along this long sheath. Letting the circular tip place 
in the lumen of MPA and PA bifurcation where SNs 
were mostly distributed [30], then ablation was 
conducted. For most animals and PAH patients, 
the mPAP and PVR were decreased immediately 
to some degree and were declining in the follow-up 
months after PADN. There was some catheter-
based PADN conducted in swine [16] and dogs 
[15], and these studies found that the SNs injury 
induced by PADN could remain for a long time, and 
PADN continually improved hemodynamic param-
eters and PA remodeling in PAH animal models 
[15, 16]. To date, catheter-based PADN has been 
applied in clinical trials. Chen et al. [30] did the 
first PADN clinical study with low-risk idiopathic 
pulmonary arterial hypertension (IPAH) patients, 
and showed that the PADN procedure can improve 
hemodynamic measurements and clinical pres-
entation quickly and effectively. In this trial, the 
systolic PAP and mPAP of 12 patients with PADN 
procedures obviously declined at once and during 
the subsequent 3 months. Furthermore, during 
the 3-month follow-up, these IPAH patients who 
performed PADN procedures showed a significant 
improvement in cardiac output and 6-min walk 
distance (6WMD). In the treatment group, just 
one procedure failed when the patient suddenly 
experienced intolerable chest pain after the first-
place ablation (three ablation places in total), but 
mPAP still reduced 6 mmHg [30]. Although this 
study has investigated hemodynamic improve-
ments and functional capacity of IPAH patients 
after PADN, the conclusion that PADN was an 
effective therapy for medication-refractory PAH 
patients was still recognized with controversies 
in the low-risk type and insufficient quantity of 
PAH patient individuals for nonrandomized trials, 
no sham populations and not enough follow-up. 
To confirm the efficacy of PADN, Chen et al. then 
performed other studies that enrolled varieties of 
patients from different centers, in different World 
Health Organization groups and were induced by 
different causes [31–33], thereafter they found that 
performing PADN in the internal surface of PA can 
still achieve a significant curative effect for those 
PAH patients who can bear chest pain induced by 
the PADN procedure after ablation. However, there 
are still some patients who cannot achieve benefits 
from this type of PADN. It is probably associated 
with the limited depth of ablation in the lumen 
and only a few SNs being destroyed. Moreover, 
the TIVUS system, a novel ultrasound energy de-
livery system using a multidirectional ultrasound 
catheter, is being observed because it can prolong 
the depth of ablation. Rothman et al. [34] lately 
conducted related animal and clinical experiments, 
and manifested that PADN using catheter-based 
ultrasonic energy can also improve states of pulmo-
nary hypertension (PH) in animal models and PAH 
patients. In addition, studies showed that many 
SNs exist in the PA adventitia. And Garcia-Lunar 
et al. [35] conducted an animal trial using a bipolar 
radiofrequency system to perform PADN in the PA 
adventitia after thoracotomy, but hemodynamic pa-
rameters of the animal models did not improve sig-
nificantly after PADN. Recently, Mahfoud et al. [36] 
reported an innovative alcohol-mediated renal 
denervation system which could infuse absolute 
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alcohol through needles being penetrated into the 
renal artery and safely decrease blood pressure in 
patients. Similarly, this system also can be used 
in PADN so that drugs  can be injected to destroy 
the SNs in the whole layer of PA, and then make 
most SNs around PA inactive aiming to minimize 
the over-activity of SNS and rein–angiotensin– 
–aldosterone system (RAAS) in a larger extent. 
Changes of sympathetic nerves after  
pulmonary artery denervation 
After PADN, the anatomic structure and func-
tions of SNs around PA both have been destroyed 
to some extent, though PADN itself cannot destroy 
all SNs. Early preclinical studies have shown that 
sympathetic nerve conduction velocity (SNCV) 
immediately changed when PADN was done. In a 
study with 41 dogs (6 control, 10 with mPAP ≤ 25 
mmHg after injected dehydrogenized monocrota-
line (DHMCT), 5 with PAH but without PADN, 
20 with PADN) was used to examine SNs, the 20 
PAH dogs induced by DHMCT underwent PADN 
at the conjunctional area between the distal MPA 
and the ostial LPA with the following parameters: 
a temperature of 45° to 50°, energy ≤ 10 W, and 
times of 120 s. Compared with the prior-PADN 
groups, the SNCV of those with mPAP ≥ 25 mmHg 
was decreased immediately after the PADN pro-
cedure. Furthermore, in the follow-up during 
3 months, SNCV was continually declining and 
eventually almost equalled the control animals. 
Nevertheless, in the study, the axon diameter 
and myelin thickness of these dogs with mPAP 
≥ 25 mmHg was noticeably higher than those 
with mPAP ≤ 25 mmHg. Compared with the sham 
group, the axon diameter and myelin thickness had 
a gradual decline in the PADN group post PADN. 
The same with SNCV, in the subsequent 3 months, 
the axon diameter was decreasing, and the myelin 
sheath was increasingly thinner over time. Even-
tually, the nerves became almost demyelinated 
[15]. These findings represented that PADN can 
induce serious and long-term SNs injury and then 
decrease the activity of SNS [6]. Furthermore, 
some studies reported that in the lung tissue, main 
components of RAAS are decreased in the PADN 
group [37], such as renin, angiotensin converting 
enzyme (ACE), angiotensin II (Ang II), Ang II type 
2 receptor (AT2 receptor), mineralocorticoid recep-
tor (MR) and Ang II type 1 receptor (AT1 receptor), 
which illustrated that the activity of RAAS was 
reduced after SNs were destroyed.
Improvements of hemodynamic  
measurements after pulmonary  
artery denervation
Animal studies
Pulmonary artery denervation can almost 
safely and effectively abolish the increases of 
mPAP in PAH animals induced by a variety of 
measures, including using balloon occlusion at the 
interlobar segment [38], injecting DHMCT [9, 15] 
and infusing thromboxane A2 [16]. These studies 
have illustrated that PADN can decrease mPAP 
immediately and mPAP continued to decline in the 
following minimum of 3 months. Eventually, the 
mPAP of these PAH models with PADN procedures 
may even be similar to the normal animals. Zhou 
et al. [15] examined the hemodynamic changes of 
dogs found that compared with the sham group, 
mPAP, right atrial pressure (RAP), systolic PAP, 
and PVR were all significantly reduced and cardiac 
output was improved in PAH dogs after the PADN 
procedure. Zhang et al. [39] also investigated that 
PADN is effective in the PAH rat models secondary 
to heart failure, which is a disease without a useful 
therapy at present.
Clinical studies
At present, only catheter-based denervation is 
applied to clinical studies, and has achieved great 
effect similar to animal studies. PADN has been 
applied to many types of PAH patients, including 
IPAH [30], PAH secondary to connective diseases, 
PAH associated with congenital heart diseases [31], 
combined pre- and post-capillary PH associated 
with left heart failure [32] and so on. For most pa-
tients, PADN can quickly and significantly improve 
hemodynamic measurements, clinical symptoms, 
functional capacity and clinical follow-up. These 
trials all indicated that PADN is a prospective 
therapy for PAH patients, but a few patients cannot 
tolerate PADN procedures for unbearable chest 
pain and some patients seem to be irresponsive 
to PADN. Studies reported that there are two key 
adrenergic receptors (ARs) in PA, namely, b-ARs 
and a1-ARs. PADN can downregulate the density 
of a1-ARs and upregulate b-ARs in lung tissues and 
then improve PA contraction and remodeling [39]. 
In these patients with little benefit from PADN, 
perhaps it was related to the capacity of regulat-
ing ARs being lost, then the constriction of PA 
cannot be mediated. Moreover, Tzafriri et al. [40] 
found that arterial microanatomy could influence 
effect of catheter-based renal denervation. They 
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demonstrated that power density did not peak at 
the arterial lumen interface where the electrode 
was located, and surrounding tissues, especially in 
water-rich tissues, like lymph nodes, could change 
power density diffusing to a certain extent. Fur-
thermore, blood vessels adjacent to electrode could 
clear power density to a great extent. Similarly, 
for those patients without benefits from PADN, 
perhaps this phenomenon was owing to those 
surrounding tissues and vessels around the elec-
trode, which changes power density diffusing, and 
then the degree of SNs destruction is insufficient 
[40]. In addition, Fujisawa et al. [41] performed 
PADN successfully after determining ablation 
sites through observing the patient’s responses 
when high-output burst electric stimulation was 
applied to PA, which made the ablation sites more 
appropriate and avoided damaging other important 
nerves at the same time. Thus, to achieve better 
benefits, PADN should be conducted individually 
and clinical studies still have a long way to go.
Conclusions
In conclusion, PADN is a prospective and ef-
fective medical therapy for PAH patients, especially 
for those with medication-refractory PAH or PAH 
patients with limited treatment options, such as 
combined pre- and post-capillary PH [42]. While 
the mechanisms of PADN are still equivocal. In 
addition, there are still many issues which are 
eager to be resolved: (1) Previous studies have 
mostly investigated the distribution, components 
of SNs in animal models, and there are insufficient 
studies with humans. (2) which layer is more suit-
able for conducting PADN? The adventitia? The 
inner surface? Or all the layers? (3) Is TPADN, 
catheter-based denervation or accurate drug-based 
ablation the best method? And there already exist 
newmethods for renal denervation [43], such as 
alcohol-mediated denervation, ultrasonic energy-
based ablation [44] and noninvasive stereotactic 
body radiotherapy [45], which brings a new di-
rection in performing PADN. (4) The long-term 
efficacy, the indications and contraindications are 
still indeterminate. These questions should be 
answered by further studies.
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